Novel approach harnessing the power of the complement system to drive potent cell depletion Single-dose study shows rapid and sustained immune cell ...
NeuroScientific Biopharmaceuticals dosed a fourth Crohn’s patient with its StemSmart therapy ahead of phase 2 trials for its ...
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an ...
Q3 2025 Earnings Call November 10, 2025 8:30 AM ESTCompany ParticipantsKate Rausch - Head of Investor RelationsPaul Bolno ...
SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of ...
Acetylation of lysine residues in the tail domain of histone H3 is well characterized, but lysine residues in the histone globular domain are also acetylated. Histone modifications in globular domain ...
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections ...
The First And Only Treatment For Adults And Children Living With Thymidine Kinase 2 Deficiency (Tk2d). <li /> Approved indication: KYGEVVITM (doxecitine and doxribtimine) powder for oral solution (2 ...
This exciting project aims to understand the reasons for changes in mussel abundance and distribution, essential to design and develop successful restoration efforts.
The CGM market is expected to experience double-digit percentage growth over the next five years, reaching nearly $29 billion ...
KYGEVVI™ (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback